Pfizer

Coronavirus cases throughout Florida are dropping, Dr. Thomas Truman says that doesn’t make getting vaccinated any less important — even for young children.

After some debate, a group of scientists advising the FDA concluded that the vaccine's benefits outweigh its risks for young children.

The Food and Drug Administration posted its review late Friday ahead of a public meeting to consider opening vaccinations to kids 5 to 11.

The companies studied a 10 microgram vaccine dose in children 5 to 11, a third of the dose used for adults, to minimize side effects and because it still prompts a strong immune response.

The White House says the U.S. has enough doses for the country's 28 million kids age 5 to 11 and has laid out a plan to get them inoculated as soon as the vaccine is authorized for the age group.

Should people who get a COVID booster get a different vaccine from their original shot? The results of a highly anticipated study suggest that in some cases the answer may be yes.

"With new cases in children in the U.S. continuing to be at a high level, this submission is an important step in our ongoing effort against #COVID19," the pharmaceutical giant said.

Pfizer and BioNTech say they plan to submit a formal request for emergency use authorization of their vaccine in young children "in the coming weeks."

How much the vaccine manufacturers stand to gain depends on how big the rollout proves to be.

At least three promising antiviral treatments for COVID-19 are being tested in clinical trials, with results expected as soon as late fall or winter.